Large-scale isotype-specific quantification of Serum amyloid A 1/2 by multiple reaction monitoring in crude sera

Journal of Proteomics

Volumn 75, Issue 7, 2012, Pages 2170-2180

  Sung, Hye Jin ^a,b,e   Jeon, Seon Ae ^a,e   Ahn, Jung Mo ^b   Seul, Kyung Jo ^b   Kim, Jin Young ^c   Lee, Ju Yeon ^c   Yoo, Jong Shin ^c   Lee, Soo Youn ^d   Kim, Hojoong ^d   Cho, Je Yoel ^a,e  

^a Seoul National University   (South Korea)

^b Kyungpook National University   (South Korea)

^c Korea Basic Science Institute (KBSI)   (South Korea)

^d Sungkyunkwan University School of Medicine   (South Korea)

^e ProtAnBio Co   (South Korea)

Author keywords

Biomarkers; Lung cancer; MRM; Proteomics; Serum; Serum amyloid A

Indexed keywords

BIOLOGICAL MARKER; SERUM AMYLOID A; SERUM AMYLOID A1; SERUM AMYLOID A2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIMIT OF QUANTITATION; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MULTIPLE REACTION MONITORING; PRIORITY JOURNAL; PROTEIN ANALYSIS; TANDEM MASS SPECTROMETRY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEIN ISOFORMS; SERUM AMYLOID A PROTEIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84862778495     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2012.01.018     Document Type: Article

References (20)

1. Henschke C.I., McCauley D.I., Yankelevitz D.F., Naidich D.P., McGuinness G., Miettinen O.S., et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet 1999, 354:99-105.
2. Valle R.P., Chavany C., Zhukov T.A., Jendoubi M. New approaches for biomarker discovery in lung cancer. Expert Rev Mol Diagn 2003, 3:55-67.
3. Makawita S., Diamandis E.P. The bottleneck in the cancer biomarker pipeline and protein quantification through mass spectrometry-based approaches: current strategies for candidate verification. Clin Chem 2010, 56:212-222.
4. Malle E., De Beer F.C. Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice. Eur J Clin Invest 1996, 26:427-435.
5. Uhlar C.M., Whitehead A.S. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 1999, 265:501-523.
6. Dai S., Wang X., Liu L., Liu J., Wu S., Huang L., et al. Discovery and identification of serum amyloid A protein elevated in lung cancer serum. Sci China C Life Sci 2007, 50:305-311.
7. Sung H.J., Ahn J.M., Yoon Y.H., Rhim T.Y., Park C.S., Park J.Y., et al. Identification and validation of SAA as a potential lung cancer biomarker and its involvement in metastatic pathogenesis of lung cancer. J Proteome Res 2011, 10:1383-1395.
8. Lange V., Malmstrom J.A., Didion J., King N.L., Johansson B.P., Schafer J., et al. Targeted quantitative analysis of Streptococcus pyogenes virulence factors by multiple reaction monitoring. Mol Cell Proteomics 2008, 7:1489-1500.
9. Lange V., Picotti P., Domon B., Aebersold R. Selected reaction monitoring for quantitative proteomics: a tutorial. Mol Syst Biol 2008, 4:222.
10. Gerber S.A., Rush J., Stemman O., Kirschner M.W., Gygi S.P. Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. Proc Natl Acad Sci U S A 2003, 100:6940-6945.
11. Kulasingam V., Smith C.R., Batruch I., Buckler A., Jeffery D.A., Diamandis E.P. "Product ion monitoring" assay for prostate-specific antigen in serum using a linear ion-trap. J Proteome Res 2008, 7:640-647.
12. Anderson L., Hunter C.L. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol Cell Proteomics 2006, 5:573-588.
13. Keshishian H., Addona T., Burgess M., Kuhn E., Carr S.A. Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol Cell Proteomics 2007, 6:2212-2229.
14. Sung H.J., Ahn J.M., Yoon Y.H., Rhim T.Y., Park C.S., Park J.Y., et al. Identification and validation of SAA as a potential lung cancer biomarker and its involvement in metastatic pathogenesis of lung cancer. J Proteome Res 2011, 10:1383-1395.
15. Pan S., Aebersold R., Chen R., Rush J., Goodlett D.R., McIntosh M.W., et al. Mass spectrometry based targeted protein quantification: methods and applications. J Proteome Res 2009, 8:787-797.
16. Kuhn E., Wu J., Karl J., Liao H., Zolg W., Guild B. Quantification of C-reactive protein in the serum of patients with rheumatoid arthritis using multiple reaction monitoring mass spectrometry and 13C-labeled peptide standards. Proteomics 2004, 4:1175-1186.
17. Fortin T., Salvador A., Charrier J.P., Lenz C., Lacoux X., Morla A., et al. Clinical quantitation of prostate-specific antigen biomarker in the low nanogram/milliliter range by conventional bore liquid chromatography-tandem mass spectrometry (multiple reaction monitoring) coupling and correlation with ELISA tests. Mol Cell Proteomics 2009, 8:1006-1015.
18. Kluve-Beckerman B., Song M. Genes encoding human serum amyloid A proteins SAA1 and SAA2 are located 18 kb apart in opposite transcriptional orientations. Gene 1995, 159:289-290.
19. Holdenrieder S., von Pawel J., Dankelmann E., Duell T., Faderl B., Markus A., et al. Nucleosomes and CYFRA 21-1 indicate tumor response after one cycle of chemotherapy in recurrent non-small cell lung cancer. Lung Cancer 2009, 63:128-135.
20. Kulpa J., Wojcik E., Reinfuss M., Kolodziejski L. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. Clin Chem 2002, 48:1931-1937.